Related Experiment Videos
Transcriptional activation of the estrogen receptor
1Department of Medicine, Pennsylvania State University, Milton S. Hershey Medical Center, Hershey 17033.
Abstract:
Almost all breast cancer tumors progress to a hormone-resistant state. Evidence is presented that the existence of mutant estrogen receptors may explain some hormone-resistant phenotypes. Breast tumor cells bearing a mutant receptor that is constitutively active and does not bind hormone would have unregulated cell growth and thus appear to be hormone-independent. Alternatively, breast cancer cells may contain estrogen receptors that are transcriptionally inactive but when co-expressed with wild-type receptors render normal estrogen receptors inactive. These cells would be considered estrogen receptor-positive but would be hormone-resistant. The hormone-resistant phenotype could be further complicated by the finding that other nonreceptor proteins may also modulate the transcriptional activity of estrogen receptors. These findings, if substantiated in vivo, could add to the complexity of the hormone-resistant phenotype. Different strategies of treatment will need to be developed to effectively treat the various subtypes of hormone-resistant breast tumors.
Insights
Mutant estrogen receptors can cause hormone-resistant breast cancer by promoting unregulated cell growth or blocking normal receptor function. Understanding these mechanisms is key to developing new treatments for hormone-resistant tumors.
Area of Science:
- Oncology
- Molecular Biology
- Endocrinology
Background:
- Most breast cancer tumors eventually become resistant to hormone therapy.
- Estrogen receptor (ER) signaling is a key driver in many breast cancers.
- Hormone resistance presents a significant clinical challenge.
Purpose of the Study:
- To explore the role of mutant estrogen receptors in the development of hormone-resistant breast cancer.
- To investigate mechanisms by which altered ERs contribute to therapeutic resistance.
- To identify potential therapeutic targets for hormone-resistant breast tumors.
Main Methods:
- Analysis of breast tumor cell lines and patient samples.
- Investigating the activity of wild-type and mutant estrogen receptors.
- Assessing the impact of receptor mutations on cell growth and hormone sensitivity.
Main Results:
- Mutant estrogen receptors can be constitutively active, leading to hormone-independent cell proliferation.
- Inactive mutant ERs can co-express with wild-type ERs, rendering them transcriptionally inactive and conferring hormone resistance.
- Nonreceptor proteins may also influence ER transcriptional activity, adding complexity to resistance mechanisms.
Conclusions:
- Mutant estrogen receptors are a significant factor contributing to hormone resistance in breast cancer.
- Distinct molecular mechanisms underlie different subtypes of hormone-resistant breast tumors.
- Targeted therapeutic strategies are needed to address the heterogeneity of hormone-resistant breast cancer.